Abstract
Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.
| Original language | English |
|---|---|
| Journal | Clinical Breast Cancer |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Estrogen receptor
- Gastrointestinal metastasis
- GI
- Lobulare carcinoma
- MBC
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement : Features and Outcomes. / Montagna, Emilia; Pirola, Sara; Maisonneuve, Patrick; De Roberto, Giuseppe; Cancello, Giuseppe; Palazzo, Antonella; Viale, Giuseppe; Colleoni, Marco.
In: Clinical Breast Cancer, 01.01.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement
T2 - Features and Outcomes
AU - Montagna, Emilia
AU - Pirola, Sara
AU - Maisonneuve, Patrick
AU - De Roberto, Giuseppe
AU - Cancello, Giuseppe
AU - Palazzo, Antonella
AU - Viale, Giuseppe
AU - Colleoni, Marco
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.
AB - Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.
KW - Estrogen receptor
KW - Gastrointestinal metastasis
KW - GI
KW - Lobulare carcinoma
KW - MBC
UR - http://www.scopus.com/inward/record.url?scp=85026515810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026515810&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2017.07.003
DO - 10.1016/j.clbc.2017.07.003
M3 - Article
AN - SCOPUS:85026515810
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
ER -